Anticoagulation Essentials! Parenteral and Oral!



Similar documents
Critical Bleeding Reversal Protocol

Session 3 Topics. Argatroban. Argatroban. Drug Use and Adverse Effects. Laboratory Monitoring of Anticoagulant Therapy

Reversal of Antiplatelet and Anticoagulant Therapy: What You Need To Know. Ronald Walsh, MD Chief Medical Officer Community Blood Services

Laboratory Testing in Patients on Novel Oral Anticoagulants (NOACs)

Dr Gordon Royle Haematologist, Middlemore Hospital

MCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August Anticoagulants

Reversal of Anticoagulants at UCDMC

Dr Gordon Royle Haematologist, Middlemore Hospital

LAMC Reversal Agent Guideline for Anticoagulants Time to resolution of hemostasis (hrs) Therapeutic Options

Anticoagulation and Reversal

3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.

48 th Annual Meeting. Non-VKA Oral Anticoagulants: Prevention & Treatment of Bleeding. Terminology. Disclosure. Public Health Impact.

Post-ISTH review: Thrombosis-I New Oral Anticoagulants 臺 大 醫 院 內 科 部 血 液 科 周 聖 傑 醫 師

The New Oral Anticoagulants: When and When Not to Use Them Philip C. Comp, M.D., Ph.D. Professor of Medicine, University of Oklahoma Health Sciences

Speaker Disclosure. Outline. Pharmacist Objectives. Patient Case. Outline 9/4/2014

Venous Thromboembolism: Long Term Anticoagulation. Dan Johnson, Pharm.D.

Anticoagulant therapy

Disclosure. New Agents for Treatment of DVT. Prevalence of DVT VTE. Normal Hemostasis 7/17/2015. Mark Oliver, MD, RVT, RPVI,FSVU

Anticoagulation Dosing at UCDMC Indication Agent Standard Dose Comments and Dose Adjustments VTE Prophylaxis All Services UFH 5,000 units SC q 8 h

2/17/2015 ANTICOAGULATION UPDATE OBJECTIVES BRIEF REVIEW: CLASSES OF ORAL ANTICOAGULANTS

Warfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab

Title of Guideline. Thrombosis Pharmacist)

Time of Offset of Action The Trial

DISCLOSURES CONFLICT CATEGORY. No conflict of interest to disclose

Xabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center

New Oral Anticoagulants. How safe are they outside the trials?

New anticoagulants: Monitoring or not Monitoring? Not Monitoring

USE AND INTERPRETATION OF LABORATORY COAGULATION TESTS IN PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN)

New Anticoagulants: What to Use What to Avoid

The laboratory and new anticoagulant drugs

New Oral Anticoagulant Drugs What monitoring if any is required?

5/21/2012. Perioperative Use Issues. On admission: During hospitalization:

Comparison between New Oral Anticoagulants and Warfarin

Stop the Bleeding: Management of Drug-induced Coagulopathy. Stacy A. Voils, PharmD, BCPS Critical Care Specialist, Neurosurgery

New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012

A PRACTICAL REVIEW OF THE NOVEL ORAL ANTICOAGULANTS

Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation

Traditional anticoagulants

The speakers have attested that their presentation will be free of all commercial bias toward a specific company and its products.

CONTEMPORARY REVERSAL OF ANTICOAGULATION

Disclosures. Objective (NRHS) Self Assessment #2

Reversing the New Anticoagulants

Use of Antithrombotic Agents In The Presence Of Neuraxial Anesthesia

The Brave New (Anticoagulant) World

Comparative Anticoagulation

2.5mg SC daily. INR target mg SC q 12 hr or 40mg daily. 10 mg PO q day (CrCl 30 ml/min). Avoid if < 30 ml/min. 2.

Coagulation issues and bridging. Joost van Veen Consultant Haematologist - STHFT

Thrombosis management: A time for change practical management with NOACs Dr Wala Elizabeth Medical Director, Bayer Healthcare

9/28/15. Dabigatran. Rivaroxaban. Apixaban. Edoxaban. From the AC Forum Centers of Excellence website: Dabigatran, Rivaroxaban, & Apixaban

New Oral Anticoagulants

Novel Oral Anticoagulants (NOACs) Prescriber Update 2013

New Anticoagulants: When and Why Should I Use Them? Disclosures

Inpatient Anticoagulation Safety. To provide safe and effective anticoagulation therapy through a collaborative approach.

The author has no disclosures

} Most common arrhythmia. } Incidence increases with age. } Anticoagulants approved for AF

Advances in An+coagula+on

STARTING, SWITCHING OR STOPPING NEW ORAL ANTICOAGULANTS: A Practical Approach

Blood products and pharmaceutical emergencies

How To Compare The New Oral Anticoagulants

New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis

Management for Deep Vein Thrombosis and New Agents

Adherence to NOACs. Disclosure. Patricia van den Bemt EAHP Hamburg 2015

Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations

TSOAC Initiation Checklist

Anticoagulant Treatment for Deep Venous Thrombosis Direct Oral Anticoagulants (NOACs)

DOACs. What s in a name? or TSOACs. Blood Clot. Darra Cover, Pharm D. Clot Formation DOACs work here. Direct Oral AntiCoagulant

Failure or significant adverse effects to all of the alternatives: Eliquis and Xarelto

How To Increase Warfarin

Are there sufficient indications for switching to new anticoagulant agents

Non- Valvular Atrial Fibrillation and Stroke Prevention: Which OAC Do I Choose. Warfarin vs the NOACs

Anticoagulants in Atrial Fibrillation

Low Molecular Weight Heparin. All Wales Medicines Strategy Group (AWMSG) Recommendations and advice

DVT/PE Management with Rivaroxaban (Xarelto)

New Oral AntiCoagulants (NOAC) in 2015

To aid practitioners in prescribing unfractionated heparin and low-molecular-weight heparins to patients.

FDA Approved Oral Anticoagulants

How To Understand The History Of Analgesic Drugs

Anticoagulation Strategies: How to Integrate the New Anticoagulants into Your Practice. B. Gail Macik, MD Professor of Medicine & Pathology

The Anticoagulated Patient A Hematologist s Perspective

Novel Anticoagulation Agents DISCLOSURES. Objectives ATRIAL FIBRILLATION TRIALS. NOAC Comparison 6/12/2015

Building a Safe Anticoagulation Program By knowing that Safety is not about numbers, Safety is about an attitude..

Update on Antiplatelets and anticoagulants. Outlines. Antiplatelets and Anticoagulants 1/23/2013. Timir Paul, MD, PhD

ANTICOAGULATION THERAPY MANAGEMENT

Objectives. Patient Background. Transitioning a Patient To & From a New Oral Anticoagulant

Now We Got Bad Blood: New Anticoagulant Reversal

Disclosures. I have served as an advisory board member, consultant, speaker, and / or received research funding from: Sanofi-Aventis

Guideline for the Prescribing of Novel Oral Anticoagulants (NOACs): Dabigatran (Pradaxa ), Rivaroxaban (Xarelto ), Apixaban (Eliquis )

Lupus anticoagulant Pocket card

Clinical Assistant Professor University of Kansas School of Pharmacy. Objectives

NnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl

The New Oral Anticoagulants (Direct Oral Anticoagulants - DOACs)

Anticoagulant Reversal

EDUCATIONAL COMMENTARY RAT POISON, GENETICS, AND MOLECULAR BIOLOGY: WHITHER THE FUTURE OF COAGULATION TESTING?

What to do in case of hemorragia. L Camoin Jau Service d Hématologie APHM Marseille

Clinical Guideline N/A. November 2013

Transcription:

Anticoagulation Essentials! Parenteral and Oral!

Anti-Xa and Anti-IIa!

Parenteral Anticoagulants! Heparin family (indirect anti-xa and anti-iia):! UFH! LMWH (enoxaparin, fondaparinux)! Direct thrombin inhibitors (anti-iia):! argatroban! bivalirudin!

Heparins: need AT!

Heparin size matters! enoxaparin! fondaparinux!

Anti-Xa vs Anti-IIa! Anti-IIa (anti-thrombin) activity a bit more potent as a thrombosis inhibitor.! Most of the time anti-xa can get the job done if enough is given.!

Anti-Xa Monitoring! Gold standard: enzymatic anti-xa assay dependent on patient s own anti-thrombin concentration.! Widely available, but has become more expensive.! Can t quantify the clinical gain for the increased cost over aptt; no studies.! Can t quantify the clinical gain of the aptt over no monitoring either; no studies.!

The aptt is Messy! Composite of increases and decreases in various factors, including anti-iia (anti-xa much less)! can cause false increases or decreases in aptt in heparinized patients.! Instruments and reagents are different.! Can t assume a fixed number range for therapeutic (e.g. 60-85 as in literature).!

Allina, 2015!

Heparin Monitoring: ANW! Anti-Xa monitoring since 1998. We will probably switch to aptt to save money.! Falsely low aptt: anti-thrombin deficiency, elevated heparin binding proteins, elevated factor VIII levels! Falsely high aptt: liver disease/vitamin K deficiency/warfarin, oral anti-xa therapy, lupus anticoagulant! Need periodic INR (not elevated by heparin)!

Are you here?! Yes! No!

Heparin Protocols! Must have institution-wide! Nurses and pharmacists! Loading doses sometimes too high or omitted! Infusion dose best if based on blood volume and age, but some are weight-only! BV = weight, height, gender!

UFH Dosing! Hospital protocols! heparin IV THERAPEUTIC protocol! heparin IV THERAPEUTIC protocol - OMIT loading dose/initial bolus! Online tools!

LMWH! enoxaparin (fondaparinux now rare)! SC; continues expensive! anti-xa based heparin/lmwh levels only way to monitor! Work in many situations, but losing to new oral anti-xa agents.!

enoxaparin! Renal dependent! Therapeutic 0.5-1.0 IU/mL to make up for loss of anti-iia activity.! Monitoring needed in extremes of weight or renal function, or excess clotting or bleeding risks.! enoxaparin SC THERAPEUTIC protocol! Online tool exists!

Heparin Bleeding! UFH is gone in 3-4 hours in most patients.! Online protamine dosing tool for rare patient.! works only a little with enoxaparin because 80% of anti-iia activity is gone!

HIT! Decreasing! 7+ days of therapy or repeat use! 50% drop in platelet count from recent level.! Venous and arterial clots!

Suspected HIT! Higher suspicion, stop heparin and test! Low suspicion, test first and stop if positive! heparin antibodies IgG specific (96% sensitive, 93% specific)! if positive, notice whether weak or strong! if negative, only 0-2% remaining chance depending on prior probability!

HIT Treatment! Stopping heparin rarely enough! argatroban pharmacy THERAPEUTIC protocol! vascular volume drug with renal clearance! anti-iia monitoring assay! TSOACs probably work! No warfarin until platelet count normal!

Oral Anticoagulants! Indirect: warfarin! reduces multiple precursor factor levels! Target specific:! dabigatran (Pradaxa): anti-iia! rivaroxaban (Xarelto): anti-xa! apixaban (Eliquis): anti-xa! edoxaban (Lixiana): anti-xa! betrixaban (??): anti-xa!

Coumarins and Vitamin K! II VII IX X C S Liver Fresh! Active Inactive Carboxylation Excess Vit K bypasses block. Active Inactive

Vitamin K factors PT VII XII PK, HMWK XI IX VIII aptt X V II Screening clotting tests! X V II TT F F

Vitamin K factor decline! Reduced II is the most important. VII IX X II

Vitamin K balance with warfarin! Normal! Therapeutic! warfarin! Large! warfarin! overdose! Vitamin K tank! Maint. K! Recycling K! Maint. K! Maint. K! Deficit! Deficit! Recycling K! Recycling K! Recycling K! In large overdose, patient may need 5 mg or more daily for up to a week to maintain normal INR.!

Vitamin K! Green and leafy. Fat soluble, absorbed in jejunum.! Bacterial synthesis in gut a minor source (may be absorbed passively in terminal ileum and colon).! Body stores are not long lived (a few weeks at best).!

Warfarin is Messy! Variation in dietary vitamin K! Genetic variation in warfarin metabolism! Drug-drug interactions! Variation in laboratory PT/INR measurements!

International Normalized Ratio! INR =! ( )! PTpatient! PTnormal! ISI ISI = Measure of reagent strength/sensitivity!

Are you sleeping?! Yes! No!

INR in Allina! All Allina hospitals now use the same instruments and reagents.! INRs agree well between hospitals.! Many Allina clinics use POC INRs which don t agree as well.! ANGMA clinic INRs performed in hospital reference labs!

Therapeutic INR: A. Fib! VTE, AF = target of 2.5

Predictors of Warfarin Dose! Actual weight (dose increases with weight)! Age (dose decreases with age)! Both account for half of variation; rest is genetics and diet! It is trial and error from the beginning.! Don t give a high initial load!

Load and No-load approach!

Warfarin protocols: ANW/ ANGMA! Online warfarin initiation and chronic control protocols are used by pharmacy in hospital and nursing in clinics.! Versions of the tools are available in the online ANW tool set.!

Warfarin Control! Organized warfarin control program (face-to-face or over the phone) improves clinical outcomes.! Patient populations make a big difference in control.! Typical published results: 50-60% of INR values in therapeutic range.!

Lupus anticoagulant & INR! Falsely high in about 10% of chronic LA patients! Cannot predict for any patient.! Confirm accuracy of INR with chromogenic factor X when at steady state.! Falsely high INR means use CFX or don t use warfarin.!

CFX and INR! Control patients: some normal pre-operative, rest on warfarin CFX %!

Temporary Warfarin Reversal! Few surgeries done with elevated INR; some at 1.5.! Dental surgery often with special mouth wash.! Warfarin held for 5 doses before procedure (last dose 6 days before)! Bridging is needed only in highest risk conditions.!

The High INR! >> 4.5: vitamin K! Oral vitamin K can work! IV vitamin K: time critical or doubt about GI absorption.! Don t use SC! High vitamin K doses may make refractory to warfarin for up to 1-2 weeks.!

Bleeding with warfarin! External bleeding:! Stop warfarin and give vitamin K (pharmacy to dose order)! FFP if volume is needed (calculator to determine how much is needed)! PCC if severe or head bleed!

PCC: Kcentra! FFP! Kcentra! II! 1! 1.1! VII! 1! 0.6! IX! 1! 1! X! 1! 1.3! Protein C! 1! 1! Protein S! 1! 0.7!

TSOAC! dabigatran (Pradaxa): anti-iia *! rivaroxaban (Xarelto): anti-xa! apixaban (Eliquis): anti-xa! edoxaban (Savaysa): anti-xa! betrixaban (??): anti-xa!

The Trouble! RCTs have had different patient risk factors (e.g. CHAD scores) and different rates of warfarin control.! Treatment benefits compared to warfarin were small and varied depending on patient risks and warfarin control.! There are no RCTs comparing different drugs so we are uncertain if one is better than another.! All have been equal to warfarin in anti-thrombosis and equal to or better in bleeding.!

The Simple Approach! We could look at tables of cost, formulary coverage, pharmacokinetics, cytochrome activity, and food effects.! OR! Look at the winners!

Winners: 2015! Formulary coverage: rivaroxaban! Lowest retail charge: edoxaban ($291/month)! rest are $329/month (warfarin = $50)! Lowest renal excretion: apixaban (27%)! rivaroxaban 66%!

Reversibility! Holding with good renal function:! rivaroxaban gone in 1-2 days! apixaban and edoxaban gone in 2-3 days! With worse kidneys, older patients, or more worry about bleeding with procedures:! add another day or two; check anti-xa!

TSOAC 2015! For a retail paying patient who wants the lowest cost: edoxaban (Savaysa)! Blue Cross: rivaroxaban (Xarelto)! Other insurance: must check copays! If money isn t an issue: apixaban (Eliquis) because of lowest renal excretion!

When will warfarin be gone?! When the monthly cost of a newer agent gets to about $100-150! AND! andexanet alpha available: immediate reversal agent entering phase 3 trials with rivaroxaban and apixaban.!